Medios AG Expands European Presence with Acquisition of Ceban Pharmaceuticals

Medios, a leading source of Specialty Pharma Solutions in Germany, announced its strategic acquisition of Ceban Pharmaceuticals B.V., a fast-growing leader in pharmaceutical compounding services, with strong market positions in the Netherlands, Belgium, and Spain. This acquisition, priced at €235.3 million cash plus 1.7 million Medios shares, is viewed as a critical move towards creating the premier European Specialty Pharma platform, with Ceban expected to generate revenues of approximately €160 million and an EBITDA-adjusted of around €29 million in 2023.

This merger not only marks a significant step in Medios' growth strategy but also positions the company to capitalize on the increasing demand for homecare, clinics, and hospitals in both the Netherlands and Belgium. Ceban’s market leadership in these countries and its expanding positions in other European markets promise substantial growth and profit margins for Medios. Moreover, the synergy from this acquisition is anticipated to enhance diversification, expand offerings, and leverage cross-selling opportunities across existing and new geographies.

Both companies emphasise the strategic value of their merger, highlighting their complementary strengths. Medios anticipates a significant increase in annual revenue and margins following the completion of the acquisition, projecting revenues in the range of €1.9 to €2.1 billion and EBITDA pre1 margins around 4.3% for FY 2024.

The transaction, expected to close in the second quarter of 2024, signals a pivotal development for Medios' European expansion ambitions. Despite the substantial financial implications, Medios forecasts reaching ambitious mid-term targets by 2025, with projected revenue around €2.15 billion and EBITDA pre of approximately €110 million.